Dura Mater-Derived Stem Cells and Method for Producing the Same
Summary
USPTO published patent application US20260098243A1 for dura mater-derived stem cells and production methods. Inventors: Sun Hwa PARK, Sung Won KIM, Seung Ho YANG, Jung Eun LEE, Hyun Ji LEE. The application, filed 2025-10-06 under Application No. 19350367, covers methods of isolating stem cells from dura mater with serum supplements and their use in cell therapeutic agents.
What changed
USPTO published patent application US20260098243A1 on April 9, 2026, covering dura mater-derived stem cells and methods for producing the same. The application (No. 19350367, filed October 6, 2025) classifies under C12N 5/0623 and describes stem cell isolation using serum or serum substitutes, with applications in cell therapeutic agents.
Affected parties including biotech companies, pharmaceutical researchers, and cell therapy developers should monitor this application as it progresses through examination. Patent protection, if granted, could provide exclusive rights to dura mater-derived stem cell production methods with mesenchymal and neuronal differentiation potential.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DURA MATER-DERIVED STEM CELLS AND METHOD FOR PRODUCING THE SAME
Application US20260098243A1 Kind: A1 Apr 09, 2026
Inventors
Sun Hwa PARK, Sung Won KIM, Seung Ho YANG, Jung Eun LEE, Hyun Ji LEE
Abstract
A dura mater-derived stem cell and a method of producing the same according to the present invention establish a method of isolating and producing stem cells from the dura mater by adding serum or a serum substitute, which is a culture supplement, to a conventionally used medium. The dura mater-derived stem cells produced by the production method of the present invention were confirmed to have excellent differentiation potency into mesenchymal and neurons and exhibit physical characteristics that enable them to maintain high cell viability when transplanted into cell therapeutic agents. Furthermore, they have been confirmed to possess inherent expression marker characteristics so that they can be effectively used in various applications including cell therapeutic agents.
CPC Classifications
C12N 5/0623 C12N 2500/14 C12N 2500/16 C12N 2500/32 C12N 2500/34 C12N 2500/38 C12N 2500/40 C12N 2500/84
Filing Date
2025-10-06
Application No.
19350367
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.